Clinical Trial Detail

NCT ID NCT02031419
Title Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

diffuse large B-cell lymphoma

Therapies

CC-122 + Spebrutinib

Onatasertib + Spebrutinib

CC-122 + Onatasertib

Rituximab

Age Groups: adult

No variant requirements are available.